- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
February 3rd 2025, 2:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.
Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC
February 3rd 2025, 1:00pm
Gastrointestinal Cancers Symposium (ASCO GI)
Clinical outcomes did not significantly differ with atezolizumab plus bevacizumab vs tremelimumab and durvalumab in treatment-naive, unresectable HCC.
Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer
February 2nd 2025, 7:15pm
PER® Winter Lung Cancer Conference
Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.
Dr Levy on the Development and Clinical Use of ADCs in NSCLC
February 2nd 2025, 7:05pm
PER® Winter Lung Cancer Conference
Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.
Shields Spotlights Lessons Learned in Limited-Stage SCLC and Areas Ripe for Further Research
February 2nd 2025, 1:00pm
PER® Winter Lung Cancer Conference
Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.
Dr Hales on the Use of Post-Operative Radiotherapy in NSCLC
February 2nd 2025, 1:45am
PER® Winter Lung Cancer Conference
Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.
Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC
February 2nd 2025, 1:20am
PER® Winter Lung Cancer Conference
Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.
Expanded Targets, Synergistic Regimens Are Needed to Propel NSCLC Beyond Anti–PD-1 Therapy
February 2nd 2025, 12:18am
PER® Winter Lung Cancer Conference
Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.
Data Help Refine Optimal Radiotherapy Approaches in Small Cell Lung Cancer
February 1st 2025, 9:04pm
PER® Winter Lung Cancer Conference
Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.
Dr Moore on the Relationship Between Biomarker Expression and Efficacy With ADCs in Ovarian Cancer
February 1st 2025, 8:53pm
Kathleen N. Moore, MD, MS, discusses the relationship between biomarker expression and efficacy with antibody-drug conjugates in ovarian cancer.
Dr Chase on the Importance of QOL and PRO Measures in Gynecologic Oncology
February 1st 2025, 8:53pm
Dana M. Chase, MD, discusses the importance of quality of life and patient-reported outcome measures in gynecologic oncology.
Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC
February 1st 2025, 1:55am
PER® Winter Lung Cancer Conference
Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.
Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC
February 1st 2025, 1:30am
PER® Winter Lung Cancer Conference
Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.
Retrospective Data Highlight FRα and B7-H4 as Potential ADC Targets in Endometrial Cancer
February 1st 2025, 12:07am
A retrospective analysis showed a high proportion of endometrial cancer samples expressed FRα or B7-H4.
ADC Development in Ovarian Cancer: What's Next for FRa and Beyond?
January 31st 2025, 11:52pm
Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.
Dr Naumann on Next-Generation Antibody-Drug Conjugates in Ovarian Cancer
January 31st 2025, 10:30pm
R. Wendel Naumann, MD, discusses next-generation antibody-drug conjugates in ovarian cancer.
Dr Lheureux on the Evolution of ADCs Since Mirvetuximab Soravtansine in Ovarian Cancer
January 31st 2025, 10:10pm
Stéphanie Lheureux, MD, PhD, discusses the evolution of antibody-drug conjugates since mirvetuximab soravtansine in ovarian cancer.
Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer
January 31st 2025, 9:29pm
Cisplatin/paclitaxel showed trend towards improved DFS vs cisplatin alone in advanced-stage ovarian cancer.
Retrospective Analysis Shows Frailty Leads to Worsened Outcomes After Surgery in Gynecologic Cancers
January 31st 2025, 8:39pm
Postoperative outcomes may be worse among patients with gynecologic cancers who are elderly or frail.
PPP2R1A Mutations Associated With Prolonged OS in High-Risk Endometrial Cancer
January 31st 2025, 8:00pm
OS outcomes with lenvatinib plus pembrolizumab were prolonged in patients with PPP2R1A-mutated vs wild-type high-risk endometrial cancer.